LIFE SAVING DRUGS PROGRAM EXPERT PANEL 21st MEETING: 25 JULY 2025

AGENDA

1. Standing business

- 1.1 Welcome, apologies and Conflicts of Interest
- 1.2 Update on actions from previous meetings
- 1.3 Correspondence
- 1.4 Report from the secretariat

2. 24 month review of existing LSDP medicines

- 2.1 Avalglucosidase alfa (Nexviazyme®) for the treatment of Pompe disease
- 2.2 Consideration of future 24 month reviews

3. Applications for new LSDP medicines

3.1 Cipaglucosidase alfa (Pombiliti®) + miglustat (Opfolda®) for the treatment of late onset Pompe disease

4. Other business